State-funded embryonic stem cell research may be geared to solving medical mysteries. But California’s efforts to secure affordable access to any resulting drugs — and a cut of their potential profits — are only generating more “what ifs” from bioscience firms and their attorneys.
Intellectual property practitioners say current legislation that would stake a state claim to $3 billion in future bond-funded stem cell research is, in parts, vague and vulnerable to challenge. And their clients, some of California’s largest bioscience companies, don’t like the bill’s proposed 25 percent state take on net licensing revenues.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
